Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
13 juin 2016 16h05 HE | Dermira, Inc.
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Prices $126 Million Public Offering of Common Stock
08 juin 2016 07h00 HE | Dermira, Inc.
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present Preclinical Data from DRM01 Acne Program at the Society for Investigative Dermatology 75th Annual Meeting
11 mai 2016 16h05 HE | Dermira, Inc.
MENLO PARK, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update
10 mai 2016 06h30 HE | Dermira, Inc.
- Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris
10 mai 2016 06h00 HE | Dermira, Inc.
- Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m....
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira’s Co-founder and Chief Medical Officer, Eugene A. Bauer, M.D., Receives Presidential Citation from the American Academy of Dermatology
14 mars 2016 07h30 HE | Dermira, Inc.
MENLO PARK, Calif., March 14, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
03 mars 2016 07h30 HE | Dermira, Inc.
MENLO PARK, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Elects Kathleen Sebelius to Board of Directors
30 sept. 2015 16h05 HE | Dermira, Inc.
MENLO PARK, Calif., Sept. 30, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present Data for DRM01 Acne Program at EADV Congress 2015
29 sept. 2015 16h05 HE | Dermira, Inc.
MENLO PARK, Calif., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...
Dermira_Logo_RGB_R4V2_M01.jpg
Skin Disposition Study Results for Dermira's DRM01 Program in Acne Presented at International Dermatology Meeting
10 sept. 2015 07h30 HE | Dermira, Inc.
MENLO PARK, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...